文献速递淋巴瘤

儿童及青少年外周T细胞淋巴瘤-非特指型:儿童肿瘤协作组非霍奇金淋巴瘤委员会综述

Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children's Oncology Group NHL Committee.
PubMed 文献 · Blood Adv · 2025-01-01

本文综述儿童及青少年外周T细胞淋巴瘤-非特指型(PTCL-NOS)的临床表现与诊断、历史治疗策略、疾病生物学认识及造血干细胞移植(HSCT)的作用。该病在儿童中虽为最常见的非间变性成熟T细胞淋巴瘤,但极为罕见且标准治疗 largely 未定义,预后谨慎。需开展儿童专项研究以阐明生物学、改进风险分层并明确靶向药物与HSCT的一线治疗作用。

要点

  • PTCL-NOS是儿童最常见的非间变性成熟T细胞淋巴瘤,但极为罕见且标准治疗未定义。
  • 儿童PTCL-NOS生存率看似优于成人前瞻性研究,但预后谨慎,治愈率远低于常见儿童NHL。
  • 需儿童专项研究阐明生物学、改进风险分层并明确靶向药物与HSCT的一线治疗作用。

核心结论

  • 儿童PTCL-NOS极为罕见且标准治疗 largely 未定义,预后谨慎,需儿童专项研究阐明生物学、改进风险分层并明确靶向药物与HSCT的一线治疗作用。

研究设计与样本

  • 儿童肿瘤协作组非霍奇金淋巴瘤委员会综述,回顾儿童及青少年PTCL-NOS的临床表现与诊断、历史治疗、疾病生物学及HSCT作用。

主要发现

  • PTCL-NOS在儿童中为最常见的非间变性成熟T细胞淋巴瘤,但极为罕见,临床与病理异质性强。
  • 成人PTCL-NOS通常呈侵袭性临床病程且预后差。
  • 儿童PTCL-NOS回顾性治疗结局报告受限于小队列、临床表现不一及治疗方案异质。
  • 儿童已发表生存率看似优于成人前瞻性研究,但预后谨慎,治愈率远低于常见儿童NHL。
  • 成人 landmark 基因谱研究已揭示分子格局并识别具预后意义的分子亚群,但儿童PTCL-NOS生物学仍不明确。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 儿童PTCL-NOS回顾性报告受限于小队列、临床表现不一及治疗方案异质。
  • 儿童PTCL-NOS生物学仍不明确。
  • 需开展儿童专项研究以阐明生物学、改进风险分层并明确靶向药物与HSCT的一线治疗作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a rare mature T-cell non-Hodgkin lymphoma (NHL) seen in both children and adults. Although it is the most common nonanaplastic mature T-cell lymphoma of childhood, it is quite rare and, therefore, the standard of care remains largely undefined. It is a disease characterized by clinical and pathological heterogeneity and is generally associated with an aggressive clinical course and poor prognosis in adults. Retrospective reports on treatment outcomes for pediatric PTCL-NOS are limited by small cohorts, variable clinical presentations, and heterogeneous treatment regimens. Although published survival rates in children appear encouraging compared with those from prospective studies in adults, the prognosis is guarded, and relatively low curative outcomes are in stark contrast to more common pediatric NHL. Although recent landmark gene profiling studies have shed light on the molecular landscape of the disease in adults, identifying molecular subgroups with prognostic significance, the biology of PTCL-NOS remains unclear in children. Here, we review the clinical presentation and diagnosis, historical treatment approaches, current knowledge of the disease biology, and the role of hematopoietic stem cell transplant (HSCT) in PTCL-NOS in children to pursue a better understanding of this heterogeneous condition and empower physicians to use this information to best support our pediatric population. Studies focusing on pediatric PTCL-NOS are required to unravel the disease biology in children, improve risk stratification, and better define upfront treatment through the role of targeted agents and HSCT, as we look to future directions of the care of children with PTCL-NOS.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Devine KJ, Schwartz L, El-Mallawany NK, et al. Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children's Oncology Group NHL Committee. Blood Adv. 2025. PMID: 39825825. doi:10.1182/bloodadvances.2024013689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。